Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX OTCMKTS:CYDY NASDAQ:ETNB NASDAQ:HROW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.11$4.58$3.21▼$7.18$1.47B0.684.67 million shs3.65 million shsCYDYCytoDyn$0.30$0.29$0.10▼$0.49$372.45M1.231.54 million shs2.12 million shsETNB89BIO$9.43+2.6%$9.80$4.16▼$11.84$1.36B1.281.49 million shs1.29 million shsHROWHarrow$39.12+2.5%$33.93$20.85▼$59.23$1.41B0.41659,886 shs618,433 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%+2.35%+39.18%+53.90%-4.08%CYDYCytoDyn0.00%+8.00%+2.41%-12.65%+147.29%ETNB89BIO+2.61%+2.17%-6.45%-0.63%+5.96%HROWHarrow+2.52%+0.77%+5.87%+51.04%-2.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.3256 of 5 stars3.52.00.04.43.02.50.6CYDYCytoDyn0.1572 of 5 stars0.02.00.00.01.10.00.6ETNB89BIO2.0061 of 5 stars3.51.00.00.02.70.80.6HROWHarrow3.6387 of 5 stars4.61.00.00.03.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$11.5088.22% UpsideCYDYCytoDyn 0.00N/AN/AN/AETNB89BIO 3.00Buy$26.29178.75% UpsideHROWHarrow 3.13Buy$64.6765.30% UpsideCurrent Analyst Ratings BreakdownLatest CYDY, HROW, ARDX, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$62.00 ➝ $63.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $64.008/8/2025ETNB89BIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.008/5/2025ARDXArdelyxWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.00 ➝ $14.007/29/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/12/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.41N/AN/A$0.58 per share10.53CYDYCytoDynN/AN/A$0.00 per share89.14($0.08) per shareN/AETNB89BION/AN/AN/AN/A$3.52 per shareN/AHROWHarrow$227.66M6.36$0.14 per share279.07$1.33 per share29.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A19.71N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)CYDYCytoDyn$3.74M$0.0129.73∞N/AN/AN/A-4.40%10/13/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A97.80N/A-4.49%-2.18%-0.35%N/ALatest CYDY, HROW, ARDX, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million7/25/2025Q4 2025CYDYCytoDynN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03CYDYCytoDynN/A0.250.25ETNB89BIO0.0715.1915.19HROWHarrow0.780.620.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%CYDYCytoDyn5.06%ETNB89BION/AHROWHarrow72.76%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%CYDYCytoDyn0.54%ETNB89BIO2.60%HROWHarrow15.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableCYDYCytoDyn201.25 billion1.25 billionNot OptionableETNB89BIO40148.31 million144.45 millionOptionableHROWHarrow18037.00 million31.39 millionOptionableCYDY, HROW, ARDX, and ETNB HeadlinesRecent News About These CompaniesB. Riley Has Positive Estimate for Harrow Q3 EarningsAugust 23 at 2:36 AM | americanbankingnews.comFox Run Management L.L.C. Takes Position in Harrow, Inc. $HROWAugust 22 at 4:16 AM | marketbeat.comFY2025 Earnings Forecast for Harrow Issued By HC WainwrightAugust 19, 2025 | marketbeat.comHC Wainwright Has Bullish Outlook for Harrow FY2025 EarningsAugust 19, 2025 | americanbankingnews.comReviewing Acusphere (OTCMKTS:ACUS) and Harrow (NASDAQ:HROW)August 19, 2025 | americanbankingnews.comConnor Clark & Lunn Investment Management Ltd. Sells 61,794 Shares of Harrow, Inc. (NASDAQ:HROW)August 18, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Stock Price Down 4.9% - What's Next?August 17, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. ...August 17, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWAugust 17, 2025 | globenewswire.comHC Wainwright Issues Optimistic Forecast for Harrow EarningsAugust 17, 2025 | marketbeat.comWilliam Blair Has Positive Outlook for Harrow Q3 EarningsAugust 17, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of Harrow Q3 EarningsAugust 17, 2025 | americanbankingnews.comHarrow (NASDAQ:HROW) Trading 3.9% Higher - Here's WhyAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWAugust 16, 2025 | gurufocus.comCantor Fitzgerald Predicts Increased Earnings for HarrowAugust 16, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Harrow Q1 EarningsAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWAugust 16, 2025 | prnewswire.comBTIG Research Forecasts Strong Price Appreciation for Harrow (NASDAQ:HROW) StockAugust 16, 2025 | marketbeat.comWilliam Blair Analysts Raise Earnings Estimates for HarrowAugust 16, 2025 | americanbankingnews.comSurging Earnings Estimates Signal Upside for Harrow (HROW) StockAugust 15, 2025 | zacks.comBest Momentum Stock to Buy for August 15thAugust 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYDY, HROW, ARDX, and ETNB Company DescriptionsArdelyx NASDAQ:ARDX$6.11 0.00 (0.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.15 +0.04 (+0.64%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.CytoDyn OTCMKTS:CYDY$0.30 0.00 (0.00%) As of 08/22/2025 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.89BIO NASDAQ:ETNB$9.43 +0.24 (+2.61%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$9.44 +0.01 (+0.05%) As of 08/22/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Harrow NASDAQ:HROW$39.12 +0.96 (+2.52%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$39.20 +0.08 (+0.20%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access